You are here

Entinostat Receives ‘Breakthrough Therapy’ Designation for Treatment of Advanced Breast Cancer

Drug set to begin phase III testing (September 11)

The FDA has designated entinostat (Syndax Pharmaceuticals) as a “breakthrough therapy” for the treatment of locally recurrent or metastatic estrogen receptor-positive (ER+) breast cancer when added to exemestane in postmenopausal women whose disease has progressed following nonsteroidal aromatase inhibitor therapy.

Entinostat is an investigational histone deacetylase inhibitor (HDACi) set to begin phase III testing in combination with exemestane in postmenopausal women with metastatic ER+ breast cancer who have progressed on hormonal therapy.

The “breakthrough therapy” designation for entinostat is based on data from the completed phase II ENCORE 301 study, in which entinostat was shown to extend both progression-free survival and overall survival when added to exemestane in postmenopausal women with ER+ metastatic breast cancer whose cancer had progressed after treatment with a nonsteroidal aromatase inhibitor.

Entinostat is an oral inhibitor of class I histone deacetylases — key enzymes that alter the structure of chromatin to control gene expression. This aberrant gene expression can result in reversible, epigenetically-based drug tolerance. Entinostat is designed to selectively target the HDAC isoforms that are most relevant to the biology of tumors, thereby normalizing dysregulated gene expression in cancer cells and restoring the cells’ sensitivity to targeted therapy.

Source: Syndax Pharmaceuticals; September 11, 2013.

Recent Headlines

Despite older, sicker patients, mortality rate fell by a third in 10 years
Study finds fewer than half of trials followed the law
WHO to meet tomorrow to decide on international public heath emergency declaration
Study of posted prices finds wild variations and missing data
Potential contamination could lead to supply chain disruptions
Delayed surgery reduces benefits; premature surgery raises risks
Mortality nearly doubled when patients stopped using their drugs
Acasti reports disappointing results for a second Omega-3-based drug
Declining lung cancer mortality helped fuel the progress